ArticleEndocrine2026
Single 0.9-mg intramuscular rhTSH dose achieves target TSH levels in differentiated thyroid carcinoma.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferentiated thyroid carcinoma (DTC) is the most common thyroid malignancy, with incidences increasing globally. Radioisotopic therapy with iodine-131 (RAI) is recommended after total thyroidectomy for patients at intermediate/high risk. A new approach that involves the use of recombinant human TSH (rhTSH) to stimulate iodine-131 uptake during RAI has long been approved. In the standard protocol, 0.9 mg of rhTSH is administered intramuscularly on two consecutive days, followed by a therapeutic dose of iodine-131 on day 3. Unlike the traditional method of levothyroxine (LT4) withdrawal, this protocol allows the continuation of LT4, avoiding the symptoms and metabolic consequences of profound hypothyroidism. However, its high cost remains an important limitation in our setting. Therefore, this study evaluated whether a single intramuscular dose (0.9 mg) of rhTSH, instead of the currently recommended two doses, is sufficient to achieve the target thyroid-stimulating hormone (TSH) level (> 30 mIU/L) currently recommended for RAI.
methodsThis prospective, cross-sectional study included 88 patients. The TSH level on day 1 (TSH D1), defined as the primary outcome, was evaluated in relation to sex, age, body weight, recurrence risk (ATA 2025), baseline TSH values, and the interval between TSH measurements.
resultsA single rhTSH dose substantially increased TSH levels to > 30 mIU/L in all patients. Age and body weight were independently associated with TSH D1.
conclusionsThese preliminary results support the potential of single-dose rhTSH as a cost-effective and clinically feasible alternative in selected patients with DTC to achieve TSH levels > 30 mIU/L. Future comparative clinical trials should assess iodine uptake, therapeutic response, and long-term oncologic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.